Kiadis Pharma's Extraordinary General Meeting of Shareholders Approves CytoSen Acquisition
Amsterdam, The Netherlands, May 29, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that at its Extraordinary General Meeting of shareholders held today at 10:00 CEST at the Amsterdam Stock Exchange (Euronext), Beursplein 5, 1012 JW Amsterdam, The Netherlands, the resolution to approve the acquisition of CytoSen Therapeutics, Inc. - the sole proposal on the agenda - was duly passed by the shareholders.
Arthur Lahr, CEO of Kiadis Pharma, commented: "We are pleased with the continued support of our shareholders as demonstrated through their approval of the acquisition of CytoSen that we obtained at our extraordinary general meeting of shareholders this morning. With the approval of the CytoSen acquisition now obtained, we will work to close the transaction in early June."
For more information, please contact: